LAKE CHARLES, La., Jan. 13, 2022 /PRNewswire/ — Wavegate Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its StimuLux™ optical reflectometry system for closed-loop adaptive modulation of spinal cord stimulation. The FDA’s Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary evidence must demonstrate a reasonable expectation that the device will provide improved effectiveness compared to the standard of care.
“We are pleased the FDA has granted Breakthrough Device designation for our novel StimuLux™ technology. This underscores the urgent need within our society for more effective treatments of chronic, debilitating pain,” said Erich Wolf, MD, PhD, Chief Executive Officer. “We are eager to closely collaborate with the FDA as Wavegate works toward advancing the state of the art.”
StimuLux™ is a component of Wavegate Corporation’s Ellipse neuromodulation platform which integrates multiple patented technologies which aim to systematically address unmet clinical needs within the neuromodulation industry.
CAUTION: StimuLux™ optical reflectometry is limited by Federal Law to investigational use only.
About Wavegate Corporation
Wavegate Corporation is a privately-held start-up neuromodulation company focused on developing and commercializing a suite of technological innovations including: waveform-independent closed-loop adaptive stimulation, a stimulation paradigm for modulation of both ascending and descending spinal cord pain pathways, new implant geometry for reduced surface contact pressures, rapid lead anchoring, and others.
Media Contact:
Marla A. Miller, JD, LLM
Corporate Secretary
marla@wavegate.us
+1-337-419-1360
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-grants-breakthrough-device-designation-to-wavegate-corporations-stimulux-301460115.html
SOURCE Wavegate Corporation
CMS compliance deadlines and heightened cybersecurity expectations are accelerating payer interoperability and utilization management modernization…
Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted…
WASHINGTON, D.C. / ACCESS Newswire / December 15, 2025 / Leading national organizations have come…
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA…
HighlightsNewly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architectureExpands the…
Lake Oswego, Oregon--(Newsfile Corp. - December 15, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a…